• RP3-340N1.2 Knockdown Reduces NSCLC Malignancy via IL-6 mRNA

  2026-07-07

  This study identifies RP3-340N1.2 as a crucial lncRNA in non-small cell lung cancer (NSCLC) progression, demonstrating that its knockdown suppresses tumor cell proliferation and migration by destabilizing IL-6 mRNA. The findings offer mechanistic insight into lncRNA-driven oncogenesis and propose RP3-340N1.2 as a potential therapeutic target for transcriptional regulation research in NSCLC.

• BX795: A Potent PDK1 Inhibitor for Precision Signaling Studi

  2026-07-07

  BX795 stands at the forefront of small molecule kinase inhibitors, enabling researchers to dissect PI3K/Akt/mTOR and innate immune pathways with nanomolar precision. This guide translates advanced literature and experimental best practices into actionable protocols for BX795, highlighting comparative advantages and troubleshooting insights that maximize data quality in cancer and immune signaling assays.

• SN-38 Disrupts FUBP1–FUSE Binding: Mechanistic Insights in C

  2026-07-06

  The referenced study demonstrates that SN-38, the active metabolite of irinotecan, and camptothecin inhibit the binding of the oncogenic transcriptional regulator FUBP1 to its DNA target FUSE. This finding uncovers a novel mechanism beyond topoisomerase I inhibition and suggests expanded therapeutic potential in cancers where FUBP1 is overexpressed.

• Streptavidin-Cy3: Precision Biotin Detection in Cancer Metas

  2026-07-06

  Explore how Streptavidin-Cy3 enables advanced, high-sensitivity biotin detection in cancer metastasis research. This article reveals a deeper scientific perspective on super-enhancer RNA-driven mechanisms and practical assay optimization, setting it apart from standard product overviews.

• LLY507: Unlocking Selective SMYD2 Inhibition for Translation

  2026-07-05

  Explore how LLY507, a highly selective SMYD2 inhibitor from APExBIO, advances translational research in cancer and renal fibrosis. This article provides mechanistic insight, protocol recommendations, and strategic guidance for leveraging LLY507 in preclinical models—supported by landmark studies and scenario-driven experimentation. Discover how LLY507 stands apart in the landscape of epigenetic modulation tools and why its precision matters for next-generation biomedical breakthroughs.

• Bifendate (DDB): Mechanistic Leverage for Translational Hepa

  2026-07-04

  This thought-leadership article explores Bifendate (DDB) as a next-generation hepatoprotection agent, focusing on its unique mechanistic profile, strategic deployment in translational research, and implications for drug-drug interactions. Integrating evidence from recent CYP3A4 modulation studies and linking to scenario-driven workflows, the piece delivers actionable insight for researchers seeking robust, reproducible liver disease models.

• Bifendate (DDB): Applied Hepatoprotection & Lipid Metabolism

  2026-07-03

  Bifendate (DDB) empowers reliable hepatoprotection and lipid metabolism research through robust autophagy inhibition and multi-targeted action. This guide delivers actionable protocols, troubleshooting strategies, and comparative insights, ensuring reproducibility and efficiency in both in vitro and in vivo hepatic models.

• MK-1775 and the Future of Precision Cell Cycle Checkpoint Re

  2026-07-03

  Explore how MK-1775, a potent Wee1 kinase inhibitor, advances precision cell cycle checkpoint abrogation and the evaluation of cancer drug responses. This article uniquely integrates in vitro assay innovation and translational workflow insights.

• Actinomycin D: Mechanistic Precision in Cancer Research

  2026-07-02

  Actinomycin D is a potent transcriptional inhibitor with validated roles in apoptosis induction and DNA damage response. Its mechanism and benchmark parameters are well-characterized for mRNA stability assays and cancer research. Proper workflow integration and awareness of its limitations are crucial for reproducible results.

• hly Gene Deletion Weakens Biofilm and Antibiotic Resistance

  2026-07-02

  This study demonstrates that deletion of the hly gene in Listeria monocytogenes significantly impairs biofilm formation and increases antibiotic sensitivity, particularly to ribosome-targeting drugs. The findings highlight hly as a pivotal regulator of biofilm integrity, motility, and virulence, with important implications for food safety and microbial control.

• α-Amanitin (SKU A4548): Precision Tool for Transcriptional S

  2026-07-01

  This article provides an evidence-based, scenario-driven guide for using α-Amanitin (SKU A4548) to enhance reproducibility and data quality in transcriptional regulation research, RNA polymerase function assays, and preimplantation embryo development studies. Learn how α-Amanitin addresses common experimental challenges, with practical protocol parameters and comparative insights for biomedical researchers.

• MDM1 Overexpression Enhances Apoptosis and Chemoradiotherapy

  2026-07-01

  The reference study identifies MDM1 overexpression as a driver of increased p53 expression and apoptosis, thereby sensitizing colorectal cancer cells to chemoradiotherapy. These findings highlight MDM1 as a promising biomarker for predicting and potentially improving treatment response in colorectal cancer.

• Phosphatase Inhibitor Cocktail 2: Streamlining Phosphoprotei

  2026-06-30

  Phosphatase Inhibitor Cocktail 2 (100X in ddH2O) by APExBIO delivers robust, broad-spectrum phosphatase inhibition, ensuring reliable protein phosphorylation preservation in cell lysates and tissue extracts. Its ready-to-use, highly concentrated format enables reproducible results in Western blotting, Co-IP, and kinase assays, even in complex workflows where signal fidelity is critical.

• Nanoparticle Uptake in Corneal Cells: Role of Endocytosis Pa

  2026-06-30

  This study systematically explores how nanoparticle size and surface chemistry affect their uptake by human cornea epithelial cells. By dissecting the endocytic pathways involved, the research identifies key design parameters for optimizing ocular drug delivery systems.

• Cucurbitacin I (JSI-124): Protocols for STAT3 Pathway Resear

  2026-06-29

  Cucurbitacin I (JSI-124) empowers researchers with precise inhibition of STAT3 signaling, enabling advanced studies of cancer cell proliferation, invasion, and in vivo tumor growth. This guide delivers actionable workflows, troubleshooting insights, and a focused translation of recent neuro-cardiac modeling advances to optimize your experimental outcomes.

450 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page